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Abstract: Equine pituitary pars intermedia dysfunction (PPID) is a neurodegenerative disease 
of the hypothalamus, resulting in the loss of dopaminergic inhibition of pars intermedia. An 
oxidative stress injury of unknown etiology has been suggested to initiate the neurodegen-
eration. While hypertrichosis (formerly known as hirsutism) is considered pathognomic for 
advanced disease, the antemortem diagnosis of subclinical and early disease has continued to 
prove difficult. Numerous tests have been used with varying sensitivities and specificities. The 
overnight dexamethasone suppression test, originally documented to have 100% sensitivity 
and specificity in horses with advanced disease, has proven to be less valuable in identifying 
early disease. Basal plasma adrenocorticotropin concentrations have improved sensitivity and 
specificity when sampled during the autumn months, and α-melanocyte-stimulating hormone, 
while not yet commercially available, shows promise as a sensitive and specific single sample 
test. Recent advances in our knowledge include the strong association between laminitis and 
hyperinsulinemia, both common clinical signs associated with PPID. The pathogenesis of hyper-
insulinemia, laminitis, and their association with this disease is a focus of current research. The 
dopamine agonist pergolide mesylate is still the mainstay of medical management, with studies 
on oral bioavailability, pharmacokinetics, and long-term survival rates now published.
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Introduction
Equine Cushing’s disease, now known as pituitary pars intermedia dysfunction (PPID), 
was first described in 1932.1 The classic clinical picture is one of advanced disease, the 
aging horse or pony with a persistent, long, curling hair coat; epaxial muscle wastage; 
pendulous abdomen; and an increased risk of laminitis.2 In recent epidemiological 
surveys, 21%–22% of aged horses and ponies had PPID based on endocrine testing, 
an increase in reported prevalence from previous studies.3–6
Considerable research into the pathophysiology of PPID has occurred in recent 
years. The current pathophysiological theory for PPID is an age-related oxidative 
stress-induced neurodegeneration of the dopaminergic neurons of the hypothalamus.7–10 
This in turn causes a loss of dopaminergic inhibition on the pars intermedia result-
ing in an increased production of pro-opiomelanocortin (POMC)-derived peptides 
including adrenocorticotropin (ACTH), α-melanocyte-stimulating hormone (α-MSH), 
β-endorphin, and corticotrophin-like intermediate peptide. Of these hormones, the 
production and actions of ACTH and α-MSH have been most closely studied and 
assessed for diagnostic test potential. The cause of the oxidative stress compared 





to age-matched controls is yet to be determined. The very 
slow progression of this disease makes the elucidation of an 
initiating cause or insult difficult as clinical signs are only 
evident after a substantial time lapse (years), when normal 
hormonal function is lost.11
In the normal pituitary, the pars distalis is responsible 
for the majority of ACTH production with small amounts 
of ACTH from melanocyte-derived POMC.9 The pars inter-
media’s primary product is α-MSH, a metabolically active 
peptide involved in metabolism and obesity, which has potent 
anti-inflammatory properties. The cortiotrophs in the pars 
distalis are under a glucocorticoid negative feedback loop. 
The production and secretion of the POMC peptides from 
the melanotropes in the pars intermedia are under dopamine 
inhibitory control from the hypothalamus. Hypothalamus and 
pituitary activities are influenced by season and photoperiod 
length, with significant up-regulation of α-MSH and ACTH 
production in the late summer and autumn months (periods 
of decreasing day length).12–14 The increased activity is seen 
in both unaffected and PPID-affected horses and ponies. 
This has a significant effect on basal endogenous ACTH 
and α-MSH levels and therefore on diagnostic testing dur-
ing this period.
In 1994, Dybdal et al described the overnight dexam-
ethasone suppression test (ODST) as a 100% sensitive and 
specific diagnostic test based on a population of horses with 
clinically advanced PPID.2 The challenge since then has been 
the diagnosis of PPID in subclinical and early clinical horses 
and ponies. Plasma POMC peptide levels are secreted along a 
concentration continuum. Horses and ponies will have normal 
to mildly elevated levels early in the disease process. There 
is a transition period or “gray zone” within this continuum, 
where hormone levels may be normal in clinically suggestive 
cases or elevated in clinically normal horses and ponies.15 
Clinically overt cases will have significantly increased plasma 
POMC concentrations than either clinically normal or early 
clinical cases. Cutoff levels for the current diagnostic tests 
are based on statistical methodology to maximize sensitivity 
and specificity. To minimize the number of false negative 
and positive results, a number of recommendations by vari-
ous equine endocrinology groups have been made including 
the use of seasonally adjusted reference ranges and further 
dynamic testing.16–18
Diagnostics
Diagnosis of PPID has included the presence of overt clinical 
signs, endogenous hormone levels including ACTH, insulin 
and cortisol levels, dynamic endocrine testing such as the 
ODST, thyrotropin-releasing hormone (TRH) stimulation test 
measuring cortisol or ACTH, combined TRH– dexamethasone 
suppression test, domperidone stimulation test, and histol-
ogy.2,19–23 Most recently, α-MSH has also been evaluated as a 
possible diagnostic option.24 Of these tests, the current recom-
mendations are the use of endogenous plasma ACTH with 
seasonally adjusted reference ranges in combination with 
suggestive clinical signs. Horses and ponies with ambiguous 
results (suggestive clinical signs with normal ACTH results) 
or in the gray zone (clinically normal horses with mildly 
elevated ACTH levels) should either be resampled during 
autumn or undergo a TRH stimulation test measuring ACTH 
to improve sensitivity.
Clinical signs
A long, wavy, or curling hair coat, known as hirsutism, has 
long been considered pathognomonic for advanced PPID 
disease. The long hair coat in horses with advanced PPID 
has recently been determined to be due to the persistence 
of hair follicles in the anagen stage and is therefore more 
correctly termed “hypertrichosis”.25 Follicles arrested in the 
anagen stage fail to shed, as occuring in PPID-affected horses 
and ponies. Hirsutism, the term commonly used to describe 
the hair coat changes in PPID-affected horses and ponies, 
has been borrowed from the medical field and refers to the 
excessive androgen-dependent growth of hair in women with 
Cushing’s disease. The term “hirsutism”, therefore, has been 
incorrectly used to describe the hair coat abnormalities seen 
in PPID.
Laminitis is commonly associated with PPID.1,9,22,26 In all, 
13% of PPID confirmed horses had a history of or concurrent 
laminitis in a recent survey.3 Historically, it was thought that 
the loss of the diurnal cortisol fluctuations with exposure to 
increased daily cortisol levels was responsible for the PPID-
associated laminitis.27,28 Recent work on the pathogenesis 
of endocrinopathic laminitis, however, has demonstrated a 
strong association with a concurrent hyperinsulinemia.29–31 
The exact mechanisms of this association and the association 
between hyperinsulinemia and PPID are currently unknown 
and are the subject of ongoing research.
Other common clinical signs include bulging supraor-
bital fat pads, lethargy or docility, epaxial muscle wastage, 
a pendulous abdomen, sweating abnormalities, polyuria/ 
polydipsia, poor wound healing, chronic infections or 
increased susceptibility to infection, endoparasitism, and very 
rarely, seizure-like activity.1,9,22,32–34 The presence of three or 
more common clinical signs (hypertrichosis, wasted epaxial 
muscles, pendulous abdomen, bulging supraorbital fat pads, 
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Table 1 ACTH upper reference ranges, sensitivity, and specificity data from different locations and seasons
Location/latitude Subtropics 
Southern hemisphere (-27° 24′ to -24° 54′)15
Temperate Northern 
hemispherea,44,46
Sn (%) Sp (%) Cutoff Cutoff
ACTH
 Autumn 100 95 77.4 pg/mL
 winter–summer 80 82 29.7 pg/mL
 Late summer to mid-autumn 47 pg/mL
 Late autumn to mid-summer 29 pg/mL
α-MSH
 Autumn 100 97 165.4 pmol/L
 winter–summer 59 93 52 pmol/L
 Late summer to mid-autumn No precise value documented
 Late autumn to mid-summer 35 pmol/L
Note: aNorthern hemisphere reference ranges have been calculated on normal distributions and 95% confidence intervals, with no sensitivity or specificity data to date.
Abbreviations: ACTH, adrenocorticotropin hormone; cutoff, upper limit of normal reference range; α-MSH, α-melanocyte-stimulating hormone; Sn, sensitivity; Sp, 
specificity.
and divergent laminar rings) in combination with a seasonally 
adjusted endogenous ACTH value has recently been docu-
mented to be the “clinically diagnostic gold standard”.3
Plasma ACTH
In the hypothalamus–pituitary–adrenal axis, ACTH secre-
tion from the pituitary stimulates the adrenal glands to 
increase the secretion of cortisol. In PPID-affected horses 
and ponies, only 20% have adrenomegaly, supporting the 
theory that the excessive ACTH produced in PPID-affected 
horses and ponies is biologically inert, resulting in ACTH-
cortisol dissociation.9,35 ACTH secretion is affected by 
numerous external factors including stress, transport, ill-
ness, marked pain, and debilitation and exercise.36–39 ACTH 
secretion is also affected by day length, with increased 
secretion associated with decreasing photoperiods during 
the late summer and autumn (Table 1).40 This effect does not 
appear to be universal though, with varying degrees of sea-
sonal fluctuations documented at different latitudes.15,41–44 
PPID-affected horses and ponies still show the greatest 
elevations. Increased plasma ACTH secretion in the autumn 
months in both normal and PPID-affected horses and ponies 
initially resulted in reluctance to measure endogenous 
plasma ACTH due to a presumed decrease in specificity 
during these months. However, recent work and determi-
nation of seasonally adjusted ACTH reference ranges has 
significantly increased the sensitivity and specificity of 
endogenous plasma ACTH levels during this period. The 
seasonally adjusted values are latitude dependent. Large, 
multicenter collaborations to establish regional seasonally 
adjusted values are needed. In lieu of these data, using a 
local laboratory with its own established reference ranges 
is recommended.
Even with the determination of seasonal variation and 
adjusted cutoff values, there still exists a transitional or 
“gray” zone.45 Horses and ponies that have endogenous 
plasma ACTH value of between 29 and 40 pg/mL (northern 
hemisphere non-autumn reference range) during the winter, 
spring, and summer months with no or few subtle clinical 
signs present a clinical dilemma and should be retested during 
the autumn when the test has greater sensitivity and speci-
ficity, decreasing the likelihood of false positive results.46 
Alternatively, a TRH stimulation test measuring ACTH, 
instead of cortisol, can be performed (see TRH stimulation 
test measuring ACTH).
Ultradian and circadian rhythms and effects of feeding 
have been investigated to optimize sample timing. No ult-
radian rhythms were found in neither unaffected or PPID-
affected horses and ponies.45 Further to this, paired sampling 
was not found to increase sensitivity and specificity.47 Rendle 
et al identified a circadian rhythm in unaffected horses 
and ponies with plasma ACTH values highest at 8 am and 
decreasing throughout the day, whereas Diez de Castro et al 
did not demonstrate a circadian rhythm in healthy horses.45,48 
A significant postprandial increase in endogenous ACTH has 
been documented, suggesting that the feeding status of the 
animal may also be a cofounder for both endogenous and 
dynamic ACTH testing.48
Sample handling and storage of plasma for endogenous 
ACTH measurement has also been investigated. Contrary 
to previous recommendations, while there is a decrease 
in endogenous ACTH levels over time, clinically relevant 
results can be obtained from chilled, non-centrifuged plasma 
processed within 48 hours of collection.9,49 Samples held 
for greater than 48 hours prior to processing should be 
centrifuged, the plasma separated and frozen while awaiting 





transport to the laboratory. The inclusion of the preservative 
N-phenylmaleimide had no effect on plasma ACTH levels 
over time.49
TRH stimulation test measuring ACTH
The TRH stimulation test originally measured cortisol 
levels 10 and 30 minutes post-TRH administration and 
had a sensitivity of 92%. Specificity, positive and negative 
predicative values were improved when combined with the 
dexamethasone suppression test.19 In horses and ponies 
with PPID though, cortisol levels are rarely elevated in the 
face of significant elevations in ACTH, suggesting that the 
melanotropic-derived ACTH is immunologically active but 
biologically inert and, therefore, dissociated from serum cor-
tisol levels.9,35 This observation has led to endogenous ACTH 
being measured 10 and 30 minutes post-TRH administration 
(Table 2), resulting in sensitivity of 94% and specificity of 
78% at 30 minutes using a cutoff of 36 pg/mL.35 In this study, 
plasma ACTH was shown to be superior than serum cortisol 
for the diagnosis of PPID.
As with endogenous plasma ACTH, the TRH stimula-
tion test is affected by season and seasonally adjusted refer-
ence ranges are needed to improve specificity. Factors that 
confound the evaluation of endogenous ACTH results will 
impact on the TRH stimulation test as well. TRH has been 
both expensive and difficult to obtain and is therefore a test 
usually performed at referral and university institutions. 
A compounded TRH product stored at room temperature has 
been assessed and found to give comparable test results. The 
availability and cost of this product outside North America 
is unknown at this time.50
Overnight dexamethasone suppression 
test
The ODST has, for many decades, been considered the “gold 
standard” antemortem diagnostic test. This was based on a 
sensitivity and specificity of 100% achieved in a population 
of horses and ponies with advanced PPID.2 The sensitivity 
and specificity in early and subclinical disease are 65% and 
76%, respectively.19 The potential induction or exacerbation 
of existing laminitis post-ODST and the requirement of 
either two visits or overnight hospitalization of the patient 
have limited the practicality of this test.1 As a downstream 
product of the hypothalamus–pituitary–adrenal axis, corti-
sol secretion is also seasonally affected. To date, there have 
been no seasonally adjusted reference ranges documented 
for the ODST.
α-Melanocyte-stimulating hormone
α-MSH is primarily derived from the pars intermedia and 
undergoes increased secretion occurring in the later sum-
mer and autumn months (Table 1).14 Its role in metabolism 
and increased secretion during periods of decreasing day 
length is a proposed survival mechanism to increase fat 
Table 2 PPiD test protocols
Test Protocol Sample type required
ACTH   • Blood collected in plastic eDTA vacutainer 
if #48 hours to laboratory processing 
  • No further processing required 
if $48 hours until laboratory processing 
  • Centrifuge sample 
  •  Separate plasma and place in a plain (red top) plastic vacutainer, marked eDTA Plasma
  • Freeze plasma and send on ice to laboratory
Plasma (eDTA)
TRH stimulation test  
measuring ACTH
  • Collect blood in plastic eDTA (purple top) tube 
  • Administer 1.0 mg (total dose) TRH intravenously 
  • Collect blood in plasma eDTA (purple top) tube 30 minutes later 
  •  Submit samples for ACTH levels (Sample handling for ACTH is outlined above)
Plasma (eDTA)
ODST 5 pm 
  • Collect blood in a plain (red top) vacutainer for basal cortisol level 
  • Administer 40 μg/kg of dexamethasone intramuscularly 
8 am–12 pm hours the next day (7 pm–12 am later) 
  •  Collect second blood sample in a plain (red top) vacutainer for second cortisol level
Serum ×2
α-MSH   • Blood collected in eDTA vacutainer Plasma (eDTA)
insulin   •  Collect blood in a plain (red top) vacutainer, preferably after a short overnight fast Serum
Oral glucose challenge   • Give 0.15 mL/kg of Karo Lyte corn syrup orally 
  •  Collect blood in a plain (red top) vacutainer for an insulin level 60–90 minutes later
Serum
Abbreviations: ACTH, adrenocorticotropin hormone; eDTA, ethylenediaminetetraacetic acid; α-MSH, α-melanocyte-stimulating hormone; ODST, overnight dexamethasone 
suppression test; PPiD, pituitary pars intermedia dysfunction; TRH, thyrotropin-releasing hormone.
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stores in preparation for anticipated feed restriction in harsh 
winters. This same mechanism may be responsible for the 
associated obesity and regional fat deposition seen in PPID 
cases. PPID-affected horses and ponies have a greater 
magnitude in plasma α-MSH levels than concurrent ACTH 
levels, suggesting that α-MSH may rise early in the disease 
process and, therefore, be a more sensitive diagnostic test.14 
Plasma α-MSH is stable in chilled, whole blood for up to 
8 hours, but does require centrifugation, plasma separation, 
and freezing prior to transportation to the laboratory, unlike 
ACTH which, when chilled, is stable in whole blood for up 
to 48 hours.14,49 α-MSH is not effected by stress, illness, 
exercise, or transportation and as such has less confounders 
on result interpretation than ACTH.14 In a recent epidemio-
logical study, α-MSH had a higher sensitivity and specificity 
than ACTH when tested in the autumn months.15 Currently, 
α-MSH assays are not commercially available and only used 
in research facilities.
insulin
Almost 90% of laminitis diagnosed is classed as endo-
crinopathic in origin.51 The initial theorized pathogenesis of 
PPID-associated laminitis was glucocorticoid induced, due to 
exposure of the lamellar tissue to increased total daily cortisol 
as a result of the cortisol diurnal secretory rhythm loss; this 
has not been clearly demonstrated in studies though.27,28,52 
Hyperinsulinemia has been repeatedly documented to cause 
laminitis in healthy non-laminitic horses and may be the major 
mechanism associated with pasture-associated laminitis.29,53 
PPID-affected horses and ponies with concurrent hyperinsu-
linemia experience laminitic episodes more frequently than 
normoinsulinemic PPID horses and ponies.31 The presence 
of PPID alone though does not impair insulin sensitivity.54 
Insulin sensitivity decreases with increasing age in equids.55,56 
The mechanism by which hyperinsulinemia induces laminitis 
and whether it is the same mechanism/s associated with PPID 
or a concurrent disease is yet to be elucidated.
Basal serum insulin concentrations or dynamic insulin 
testing should be undertaken in horses and ponies with PPID 
and laminitis. The presence of a concurrent hyperinsuline-
mia will influence the management and feeding practices 
implemented. To standardize testing, samples for basal serum 
insulin should be taken in the morning after an overnight 
fast. A small biscuit of good quality given and consumed 
before 10 pm is allowed. Insulin levels greater than 20 IU/L 
are considered hyperinsulinemic.57 Dynamic testing has 
the added benefit of assessing postprandial insulin levels 
(the pancreatic β-cells response to a glucose challenge). 
Dynamic testing involves the oral administration of 0.15 
mL/kg of corn syrup (ACH Food Companies, Karo Lyte, 
Cordova, TN, USA) orally after a short overnight fast (ie, 
a small biscuit of hay given, consumed, and any remainder 
removed before 10pm the night before), and serum insulin 
samples taken 60 and 90 minutes later. Serum insulin of less 
than 45 IU/L at both time points is found in healthy horses. 
Serum insulin levels between 45 and 60 IU/L are equivo-
cal and greater than 60 IU/L is evidence of postprandial 
hyperinsulinemia and insulin dysregulation.58 Alternatively, 
1 g/kg of dextrose powder can be fed in a small meal of chaff 
or low-sugar chopped feed and mixed in water after a short 
overnight fast. Serum insulin levels are measured 60 min-
utes later. Insulin levels greater than 85 IU/L are considered 
diagnostic for hyperinsulinemia.59 Other tests include the 
combined insulin and glucose test and the insulin tolerance 
test. Neither of these tests assesses both the pancreatic secre-
tion and clearance of insulin. They also require more time 
and sampling with more confounders when compared with 
the oral glucose tests.60
Histopathology
For many other diseases, confirmation of a previously 
described histopathological appearance is considered the 
gold standard to which all antemortem tests are compared. 
Confirmation of the disease on histopathology is therefore 
used to calculate the sensitivity and specificity of a given 
antemortem test. This test standard has been unreliable in 
PPID, with documented inconsistencies between pathologists 
on classification of histological changes and therefore final 
diagnosis.23 The pituitary architecture and size is also subject 
to seasonal variation.61 The current accepted description is a 
hyperplastic pars intermedia with a singular large or multiple 
small adenomas.9
Treatment
There is currently no cure for PPID. Pergolide mesylate, an 
ergot-derived D2-dopamine agonist, is still the drug of choice 
for the medical management of PPID.9 The replacement of 
dopamine and reestablishment of dopamine inhibition on the 
POMC-derived peptides results in normalization of pituitary 
hormone levels and resolution of clinical signs.
Management
PPID-affected horses and ponies require excellent hus-
bandry and management practices. The presence of insulin 
dysregulation and postprandial hyperinsulinemia requires 
careful dietary management.62 Horses and ponies with a 





history of laminitis or documented hyperinsulinemia require 
restricted access to diets high in soluble nonstructural carbo-
hydrates, including lush or fast-growing pastures and sweet 
feeds to decrease the frequency of laminitic episodes.63 The 
use of a grazing muzzle aids in dietary restriction without 
restricting exercise. Grazing should be restricted from 
mid-morning to late afternoon, as wilting increases the 
sugar content in the pasture. Likewise, grazing should be 
restricted after a harsh frost as this also increases the sugar 
content of pasture. Soaking hay for 60 minutes in cold water 
will also decrease the sugar content. All PPID-affected 
horses and ponies benefit from the feeding of good quality 
senior diets to provide adequate protein intake to minimize 
muscle catabolism.
PPID-affected horses and ponies are more likely to suf-
fer from moderate to severe endoparasitism compared with 
age-matched controls.33 PPID horses and ponies tend to be 
the “high egg shedders” in the herd and have a shorter egg 
reemergence period post-worming than their herd mates. 
A deworming program which incorporates regular fecal egg 
counts and fecal egg reduction test is optimal.
Regular dental checks and vaccinations are recom-
mended. PPID horses and ponies, while having an increased 
susceptibility to infections, continue to have adequate 
immune responses to vaccination.64,65 The degree of response 
and duration of immunity may vary depending on severity 
of disease compared with age-matched controls. Further 
research is required to further quantify these changes and 
assess whether a change in vaccination dosage frequency 
should be recommended. Early and aggressive medical 
management of infections is also needed.
Pergolide mesylate
Pergolide mesylate is available in Australia and New  Zealand 
as a liquid (Ranvet Pty Ltd, Ranvet’s Pergolide, East Botany 
NSW, Australia) and as a tablet (Boehringer Ingelheim, 
Prascend, Ingelheim am Rhein, Rhineland-Palatinate, 
 Germany). Only the tablet form is commercially available 
in the UK, Europe, and North America. The 200 mg/mL 
liquid formulation allows for very accurate dosing. Pergolide, 
however, is unstable and light sensitive in the liquid form, 
with a short 3-month shelf life, potentially resulting in drug 
wastage and extra cost to the client. The tablet formulation 
is more stable with a shelf life of up to 24 months. The 1 mg 
tablets are half-scored allowing for one division and a dosage 
accuracy of 0.5 mg. Compounded pergolide mesylate has 
shown itself to be unreliable in both drug distribution and 
stability and is not recommended for use.66
The current recommended dose rate is 0.002 mg/kg once 
daily orally.9 Lower doses have been successfully used.34,67 Once 
clinical and biochemical resolution has been achieved, the dose 
should be titrated down to the lowest effective dose to prevent 
side effects such as anorexia, sweating, colic, diarrhea, and 
neurological signs.68 These side effects are most commonly seen 
at higher dose rates (0.01 mg/kg) and can be avoided by starting 
at a lower dose rate and gradually increasing the dose if needed 
over a period of weeks. Dosage efficacy is based on the demon-
stration of normalized plasma ACTH levels and the resolution 
of clinical signs. It should be noted that hair coat shedding will 
not be seen until the spring, regardless of appropriate dosage 
administration, due to the day length effect on α-MSH.
The serotonin antagonist cyproheptadine is no longer con-
sidered useful either alone or in conjunction with pergolide 
due to the lack of efficacy achieved above that attributed to 
either management or pergolide.68
Conclusion
The last 3 decades has seen considerable expansion in our 
knowledge of PPID. There is still much to learn though. 
A “gold-standard” antemortem diagnostic test continues 
to be elusive. Currently, basal plasma ACTH is the most 
sensitive and specific test commercially available for early 
diagnosis. The sensitivity and specificity increase if sampling 
occurs during the autumn months. Dynamic testing using 
the TRH stimulation test measuring ACTH is also useful in 
detecting early clinical disease. α-MSH shows promise as 
a single sample diagnostic test, but is not yet commercially 
available. Pergolide is still the drug of choice for medical 
management of clinical signs and, when used in conjunc-
tion with improved husbandry and management practices, 
can significantly improve the quality and duration of life of 
PPID horses and ponies for many years.
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